Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - eplerenone, quantity: 25 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; croscarmellose sodium; magnesium stearate; iron oxide yellow; microcrystalline cellulose; iron oxide red; purified talc; lactose monohydrate; macrogol 6000 - eplerenone is indicated to reduce the risk of: - cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3?14 days of an acute myocardial infarction (see clinical trials and dosage and administration). - cardiovascular mortality and morbidity in adult patients with nyha class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef ? 30% or lvef ? 35% in addition to qrs duration of > 130 msec), in addition to standard optimal therapy (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - eplerenone, quantity: 50 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; iron oxide yellow; titanium dioxide; lactose monohydrate; macrogol 6000; hypromellose; purified talc; magnesium stearate; iron oxide red - eplerenone is indicated to reduce the risk of: - cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3?14 days of an acute myocardial infarction (see clinical trials and dosage and administration). - cardiovascular mortality and morbidity in adult patients with nyha class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef ? 30% or lvef ? 35% in addition to qrs duration of > 130 msec), in addition to standard optimal therapy (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - eplerenone -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - eplerenone -

United States - English - NLM (National Library of Medicine)

apotex corp - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone tablets are indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s j

United States - English - NLM (National Library of Medicine)

american health packaging - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone tablets are indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction less than or equal to 40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - eplerenone - film coated tablet - 50 milligram - eplerenone - aldosterone antagonists - eplerenone is indicated: in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular (cv) mortality and morbidity in stable patients with left ventricular dysfunction (lvef
40 %) and clinical evidence of heart failure after recent myocardial infarction (mi). addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with new york heart association (nyha) class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef
30%)

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 50 mg - serum potassium levels should be measured before initiating eplerenone therapy and eplerenone should not be prescribed if serum potassium is >5.5 meq/l. [see 4 contraindications]. eplerenone is indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone is indicated for the treatment of hypertension. eplerenone may be used alone or in combination with other antihypertensive agents. for all patients eplerenone tablets are contraindicated in all patients with: - serum potassium >5.5 meq/l at initiation, - creatinine clearance ≤30 ml/min, or - concomitant administration of strong cyp3a4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). [see drug interactions , 7.1 cyp3a4 inhibitors, clinical pharmacology , 12.3 pharmacokinetics.]  for patients treated for hypertension eplerenon

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - serum potassium levels should be measured before initiating eplerenone therapy and eplerenone should not be prescribed if serum potassium is >5.5 meq/l. [see 4 contraindications]. eplerenone is indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone is indicated for the treatment of hypertension. eplerenone may be used alone or in combination with other antihypertensive agents. for all patients eplerenone tablets are contraindicated in all patients with: - serum potassium >5.5 meq/l at initiation, - creatinine clearance ≤30 ml/min, or - concomitant administration of strong cyp3a4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). [see drug interactions , 7.1 cyp3a4 inhibitors, clinical pharmacology , 12.3 pharmacokinetics.]  for patients treated for hypertension eplerenon

Canada - English - Health Canada

genmed a division of pfizer canada ulc - eplerenone - tablet - 25mg - eplerenone 25mg - mineralocorticoid (aldosterone) receptor antagonists